Original Article
A Recessive Form of the Ehlers–Danlos Syndrome Caused by Tenascin-X Deficiency
N Engl J Med 2001; 345:1167-1175October 18, 2001
- Abstract
Background
The Ehlers–Danlos syndrome is a heritable connective-tissue disorder caused by defects in fibrillar-collagen metabolism. Mutations in the type V collagen genes account for up to 50 percent of cases of classic Ehlers–Danlos syndrome, but many other cases are unexplained. We investigated whether the deficiency of the tenascins, extracellular-matrix proteins that are highly expressed in connective tissues, was associated with the Ehlers–Danlos syndrome.
Methods
We screened serum samples from 151 patients with the classic, hypermobility, or vascular types of the Ehlers–Danlos syndrome; 75 patients with psoriasis; 93 patients with rheumatoid arthritis; and 21 healthy persons for the presence of tenascin-X and tenascin-C by enzyme-linked immunosorbent assay. We examined the expression of tenascins and type V collagen in skin by immunohistochemical methods and sequenced the tenascin-X gene.
Results
Tenascin-X was present in serum from all normal subjects, all patients with psoriasis, all patients with rheumatoid arthritis, and 146 of 151 patients with the Ehlers–Danlos syndrome. Tenascin-X was absent from the serum of the five remaining patients with Ehlers–Danlos syndrome, who were unrelated. Tenascin-X deficiency was confirmed in these patients by analysis of skin fibroblasts and by immunostaining of skin. The expression of tenascin-C and type V collagen was normal in these patients. All five of these patients had hypermobile joints, hyperelastic skin, and easy bruising, without atrophic scarring. Tenascin-X mutations were identified in all tenascin-X–deficient patients; one patient had a homozygous tenascin-X gene deletion, one was heterozygous for the deletion, and three others had homozygous truncating point mutations, confirming a causative role for tenascin-X and a recessive pattern of inheritance.
Conclusions
Tenascin-X deficiency causes a clinically distinct, recessive form of the Ehlers–Danlos syndrome. This finding indicates that factors other than the collagens or collagen-processing enzymes can cause the syndrome and suggests a central role for tenascin-X in maintaining the integrity of collagenous matrix.
Media in This Article
Figure 1
Detection of Tenascin-X in Culture Medium and Serum.Figure 3
Pedigrees of the Five Tenascin-X–Deficient Patients.Article Activity
- Article
The Ehlers–Danlos syndrome is a genetically heterogeneous group of heritable connective-tissue disorders characterized by hyperextensible skin, hypermobile joints, and tissue fragility.1,2 Ultrastructural studies of the skin in the Ehlers–Danlos syndrome frequently reveal abnormal heterotypic collagen fibrils containing collagen types I, III, and V, indicating that the syndrome is a disorder of the collagen fibril.3 This concept is supported by the identification of mutations in genes encoding the fibrillar collagens or collagen-modifying enzymes in patients with the Ehlers–Danlos syndrome.4-12 Thirty to 50 percent of patients with classic Ehlers–Danlos syndrome have haploinsufficiency of the gene encoding type V collagen (COL5A1).13,14 Thus, although type V collagen mutations are an important cause of classic Ehlers–Danlos syndrome, other genes are probably involved in its pathogenesis.
The tenascins are a family of at least three structurally similar extracellular-matrix proteins.15 Two of them, tenascin-C and tenascin-X, are expressed in the tissues affected in the Ehlers–Danlos syndrome, including skin, tendons, muscle, and blood vessels.16-20 This pattern suggests a potential role in the Ehlers–Danlos syndrome.
Tenascin-X is a large extracellular-matrix protein that was originally identified because the gene encoding it overlaps CYP21, the gene that encodes steroid 21-hydroxylase.21,22 We previously described a patient with a contiguous-gene syndrome consisting of congenital adrenal hyperplasia (due to 21-hydroxylase deficiency) and classic Ehlers–Danlos syndrome (apparently due to deficiency of tenascin-X).23 In that index patient, tenascin-X protein and messenger RNA were absent from skin and cultured skin fibroblasts, and a large deletion encompassing all of CYP21 and part of the tenascin-X gene was found on one allele. Although the findings in this patient suggested an essential function for one of the tenascins in vivo,24,25 it remained unclear whether Ehlers–Danlos syndrome due to tenascin-X deficiency is dominant or recessive. Furthermore, it was not known whether isolated deficiency of tenascin-X without congenital adrenal hyperplasia occurs, and if so, whether it causes the Ehlers–Danlos syndrome. Because tenascin-X is a secreted protein, we identified tenascin-X in normal serum and then developed protein-based assays to measure tenascin-X and tenascin-C in serum samples collected from patients with the Ehlers–Danlos syndrome.
Methods
Study Population
The human-research committees of both participating institutions approved the study protocol, and all patients gave written informed consent. Serum was obtained from 151 patients with the Ehlers–Danlos syndrome, who were identified through the Dutch Ehlers–Danlos syndrome organization. The referring diagnosis was classic Ehlers–Danlos syndrome in 35 patients, isolated joint hypermobility in 87, and vascular-type Ehlers–Danlos syndrome in 1; 28 patients were unclassified. Serum was also collected from 21 normal persons, 75 patients with psoriasis, and 93 patients with rheumatoid arthritis. The samples were stored at –20°C until used.
Five tenascin-X–deficient persons and their available relatives were examined by one of us according to the criteria of Beighton et al. for Ehlers–Danlos syndrome subtypes.2 We used the nine-point Beighton scale to score joint hypermobility. Patients received a score of 1 for each fifth finger dorsiflexed more than 90 degrees, 1 for each thumb apposed to the wrist, 1 for each elbow hyperextended more than 10 degrees, 1 for each knee hyperextended more than 10 degrees, and 1 if the palms could be placed on the floor with the knees locked; the maximal score was 9 points. A score of 5 or more defines hypermobility. Skin hyperelasticity was scored on a three-point scale (0, 1, or 2); higher scores indicate greater elasticity. Two 4-mm punch-biopsy specimens of the skin were obtained from the upper thigh of each tenascin-X–deficient person for culture of dermal fibroblasts and immunohistochemical studies.
Enzyme-Linked Immunosorbent Assay, Immunohistochemical Analysis, and Western Blotting
Tenascin-X was detected with a rabbit polyclonal antiserum23,26 and a new guinea pig antiserum, both raised against a 100-kD carboxy-terminal fragment of human tenascin-X expressed in Escherichia coli. Tenascin-C was detected with mouse monoclonal antibody T2H527 and A107 rabbit polyclonal antiserum (Telios, La Jolla, Calif.). No cross-reactivity between tenascin-X and tenascin-C was found. Tenascin-C in serum was measured by enzyme-linked immunosorbent assay (ELISA) according to the method described by Latijnhouwers et al.,28 with a lower limit of detection of 5 ng per milliliter. Tenascin-X was measured with use of a sandwich ELISA with affinity-purified rabbit anti–tenascin-X for antigen capture. Detection of tenascin-X was performed with use of guinea pig anti–tenascin-X, followed sequentially by biotinylated goat anti–guinea pig immunoglobulin and peroxidase-conjugated avidin–biotin complex (Vector Laboratories, Burlingame, Calif.). The lower limit of detection of the ELISA for tenascin-X was 100 pg per milliliter.
A semiquantitative ELISA was first used to screen patients with the Ehlers–Danlos syndrome, normal subjects, and patients with psoriasis or rheumatoid arthritis in a single (1:50) dilution of serum. For the quantitative determination of tenascin-X (Table 1Table 1
Serum Levels of Tenascin-X and Tenascin-C.), we tested serial dilutions of serum. Patients with Ehlers–Danlos syndrome and control populations were compared by analysis of variance with post hoc testing by Duncan's multiple-range test.We immunostained cryosections of skin-biopsy specimens for tenascin-X and tenascin-C using the antiserums described above. Paraffin sections were stained with hematoxylin and eosin or an antiserum to collagen V (Dako, Carpinteria, Calif.). Secondary antiserums (biotinylated antirabbit or anti–guinea pig immunoglobulin) were followed by peroxidase-conjugated avidin–biotin complex and aminoethylcarbazol as the chromogenic substrate (Vector Laboratories). Western blotting of serum and fibroblast-culture supernatant was performed as described previously.23
Cell Culture
First to third passages of human skin fibroblasts were used. Cells were grown in Dulbecco's modified Eagle H21 medium (GIBCO BRL, Rockville, Md.), supplemented with 10 percent fetal-calf serum, L-ascorbic acid (20 μg per milliliter), penicillin, and streptomycin. Conditioned medium was harvested from confluent cultures for assay of tenascin-X by ELISA and Western blotting.
Mutation Detection
Genomic DNA was prepared from peripheral blood or fibroblasts, and polymerase-chain-reaction (PCR) detection of the 30-kb tenascin-X deletion was carried out as previously described.23 The coding sequence of tenascin-X was PCR-amplified with 23 primer pairs, with annealing at 62°C and extension for 2.5 minutes at 72°C for 35 cycles. The 12.5-kb region coding for tenascin-X was sequenced directly from PCR products with use of 42 primers. The sequences of primers used for PCR and DNA sequencing and the sizes of amplified products are available as Supplementary Appendix 1
Supplementary Appendix 1. Primer Sequences for Amplification and Complete Sequencing of the Tenascin-X Coding Sequence. with the full text of this article at http://www.nejm.org.Results
Absence of Tenascin-X in Serum from Patients with the Ehlers–Danlos Syndrome
Tenascin-X is normally secreted by skin fibroblasts as a 450-kD protein that can be detected with antibodies directed against its carboxy terminal (Figure 1Figure 1
Detection of Tenascin-X in Culture Medium and Serum.). Because tenascin-C is found in serum, we tested normal human serum for the presence of tenascin-X. Tenascin-X is also readily detected in normal serum, but the serum form of tenascin-X is a 140-kD protein probably resulting from proteolytic cleavage or alternative splicing of tenascin-X (Figure 1). To confirm that the immunoreactive species in serum is derived from the tenascin-X gene, we verified that the serum of the tenascin-X–deficient index patient23 also lacked tenascin-X (Figure 1).Tenascin-X was readily detected by ELISA in serum from 21 healthy subjects and from 146 of 151 patients with the Ehlers–Danlos syndrome. However, five unrelated patients with the Ehlers–Danlos syndrome (designated Patients 1, 2, 3, 4, and 5) lacked tenascin-X. We also tested serum from 75 patients with psoriasis and 93 patients with rheumatoid arthritis to determine whether tenascin-X deficiency was a nonspecific result of skin or joint disease. Tenascin-X was present in the specimens from all these patients.
We repeated the ELISA at multiple dilutions of serum, using samples from the five tenascin-X–deficient patients, normal subjects, patients with classic Ehlers–Danlos syndrome who were not deficient in tenascin-X in the initial screening, and patients with psoriasis (Table 1). The control groups had similar serum concentrations of tenascin-X, but tenascin-X was again undetectable in serum samples from the five tenascin-X–deficient patients. Although tenascin-C is coexpressed with tenascin-X in tissues affected by the Ehlers–Danlos syndrome, all the patients had normal serum tenascin-C levels (Table 1).
Tenascin-X Deficiency in Skin and Fibroblasts of Patients with the Ehlers–Danlos Syndrome
Tenascin-X was readily detected in conditioned medium from cultures of normal skin fibroblasts by Western blotting (Figure 1) and ELISA, although the mean (±SD) amount of tenascin-X found in conditioned medium (0.54±0.06 ng per milliliter in 48-hour supernatants of confluent cells) was substantially less than in serum. As expected, Western blotting and ELISA did not detect tenascin-X in medium conditioned by fibroblasts of the five patients who lacked tenascin-X in their serum, a result that confirmed that these patients had tenascin-X deficiency.
Histologic examination of skin-biopsy specimens from tenascin-X–deficient patients revealed no gross morphologic abnormalities, although the collagen network in the papillary dermis appeared less dense (Figure 2EFigure 2
Histopathological Findings in Skin in Patients with Tenascin-X Deficiency.) than in specimens of normal skin (Figure 2A). Immunostaining showed abundant expression of tenascin-X throughout the dermis of normal skin (Figure 2B), whereas tenascin-X was completely absent in skin from patients who lacked tenascin-X in their serum (Figure 2F). Tenascin-C and type V collagen were expressed normally in dermis of tenascin-X–deficient persons (Figure 2C, Figure 2D, Figure 2G, and Figure 2H).Clinical Findings in Tenascin-X Deficiency
All five tenascin-X–deficient patients and three clinically affected tenascin-X–deficient siblings had hyperelastic skin and hypermobile joints (Table 2Table 2
Clinical Characteristics of Five Tenascin-X–Deficient Patients and Three Affected Siblings. and Figure 2I and Figure 2J), fulfilling major diagnostic criteria for classic Ehlers–Danlos syndrome. Minor diagnostic criteria supporting the diagnosis of classic Ehlers–Danlos syndrome in the tenascin-X–deficient patients and their siblings included easy bruising in all, velvety skin in seven, joint pain in two, and multiple subluxations in three. No delayed wound healing or atrophic scars were noted. For this reason and because of the absence of evidence of dominant inheritance, four of the five patients were unclassified at the time of referral. Of the eight tenascin-X–deficient patients, only Patient 3 had coexisting congenital adrenal hyperplasia.None of the parents of the five patients with tenascin-X deficiency were related, and none of the four parents available for study (from the families of Patients 1, 2, and 3) had clinical signs of the Ehlers–Danlos syndrome. The father of Patient 1 had mitral insufficiency, and the father of Patient 2 had atrial arrhythmias and had had a cerebrovascular accident.
These tenascin-X–deficient patients also had a range of additional clinical findings not frequently associated with the Ehlers–Danlos syndrome (Table 2). These included congenital adrenal hyperplasia, spina bifida occulta, mitral-valve prolapse, stroke, gastrointestinal bleeding, and premature arteriosclerosis. Although these conditions contributed substantially to the disability of this cohort of tenascin-X–deficient patients, it is not yet clear whether these additional disorders were related to tenascin-X deficiency or were unrelated coexisting conditions.
Genetics of Tenascin-X Deficiency
The complete absence of tenascin-X messenger RNA and protein in our index patient suggested that tenascin-X deficiency is recessive.23 The index patient's phenotypically normal parents and siblings each shared one tenascin-X allele with him, providing further evidence of a recessive pattern of inheritance. However, only the index patient's paternal tenascin-X allele carried a gene deletion, and complete sequencing of the tenascin-X gene failed to identify a second mutation.
The present study allowed us to reexamine whether isolated tenascin-X deficiency is dominant or recessive (Figure 3Figure 3
Pedigrees of the Five Tenascin-X–Deficient Patients.). In three of the families we studied (those of Patients 3, 4, and 5), the patient was the only affected member and both parents were phenotypically normal, a situation consistent with recessive inheritance or with the presence of new dominant mutations in each patient. In the other two families (those of Patients 1 and 2), there were three clinically affected siblings of patients, all of whom were tenascin-X–deficient. The presence of two or more affected siblings makes new mutation an unlikely mechanism of disease in these families. Furthermore, clinical Ehlers–Danlos syndrome and tenascin-X deficiency were confined to members of one generation in all five families, also evidence of recessive inheritance. Finally, we measured serum tenascin-X levels in 12 parents and children of tenascin-X–deficient patients, who would be obligatory heterozygotes if tenascin-X deficiency were recessive. The mean serum tenascin-X concentration in these persons was approximately half that in controls (Table 1), a result consistent with haploinsufficiency and strongly supporting the hypothesis of recessive inheritance.Mutation Detection
We tested the tenascin-X–deficient patients for the 30-kb deletion described in the index patient.23 This deletion creates a fusion gene of tenascin-X and XA, a partial duplicate of tenascin-X. The XA gene has an internal deletion that truncates its open reading frame, rendering XA and the fusion gene nonfunctional. The fusion gene can be amplified independently of the normal tenascin-X gene by allele-specific PCR (Figure 4AFigure 4
Mutation Analysis of the Tenascin-X Gene.). Patient 3 had the same contiguous-gene syndrome as the index patient, but unlike the index patient, she was homozygous for the deletion, which explains both the presence of Ehlers–Danlos syndrome and that of congenital adrenal hyperplasia (Figure 4B). Both her parents and two siblings were heterozygous for the deletion and were clinically normal, providing evidence of recessive inheritance in this family.We next sequenced the tenascin-X gene in the remaining patients to identify point mutations or small insertions or deletions. In Patient 1, we found a homozygous 2-bp deletion in exon 8 that encoded the fourth fibronectin type III repeat (Figure 4C). This deletion alters the open reading frame, affecting amino acids 1184 through 1230, after which a premature stop codon is encountered (not shown). The clinically normal father of this patient was heterozygous for the deletion (Figure 4C). We could not examine the mother because she had died (Figure 3), but we found that one of her sisters carried the deletion. It is therefore likely that the mother of Patient 1 also carried this mutation, which would be consistent with recessive inheritance. Patient 5 was also homozygous for this mutation, but her parents were unavailable for study.
Patient 4 carried a homozygous 2-bp insertion in exon 3, encoding the epidermal growth factor–like repeats of tenascin-X (Figure 4D). The insertion of guanosine and thymine replaced the glutamic acid residue at position 707 with a stop codon. Additional family members were not available for study.
Patient 2 was heterozygous for the 30-kb deletion and did not have congenital adrenal hyperplasia. We were unable to identify a second tenascin-X mutation in this patient, although we sequenced the entire tenascin-X gene. This patient, like our index patient, may have had a mutation in factors, not yet defined, that regulate tenascin-X gene expression.
Finally, we wondered whether missense mutations in tenascin-X could also cause classic Ehlers–Danlos syndrome. To answer this question, we sequenced the entire tenascin-X gene in 10 patients who had classic Ehlers–Danlos syndrome and normal serum levels of tenascin-X. In these patients, we identified 26 DNA polymorphisms, 8 of which change an amino acid (data not shown). However, all 8 polymorphisms were identified in a cohort of 48 normal persons, demonstrating that these polymorphisms do not by themselves cause disease.
Discussion
This study defines a form of the Ehlers–Danlos syndrome that is both clinically and genetically distinct from previously described types.2 All tenascin-X–deficient patients fulfilled three criteria for the Ehlers–Danlos syndrome: they had hyperelastic skin, hypermobile joints, and fragile tissue, manifested as easy bruising. Although the clinical findings of tenascin-X deficiency are similar to those of the classic type of Ehlers–Danlos syndrome, the tenascin-X–deficient patients we studied lacked atrophic scars, a major diagnostic criterion for the classic type. Delayed wound healing is also found frequently in patients with classic Ehlers–Danlos syndrome. Delayed wound healing was found in our index patient but was not a prominent feature of the present cohort. Whether delayed wound healing is a rare finding in tenascin-X deficiency or is a consequence of the treatment of congenital adrenal hyperplasia with glucocorticoids is not clear.
Tenascin-X deficiency is also distinguished from classic Ehlers–Danlos syndrome by its mode of inheritance. Classic Ehlers–Danlos syndrome is an autosomal dominant disorder. Tenascin-X deficiency is recessive, as shown by the occurrence of Ehlers–Danlos syndrome in only one generation in each family; the complete absence of tenascin-X protein from the serum, skin, and fibroblast-conditioned medium of affected persons; the lack of a clinical phenotype in parents and offspring with tenascin-X haploinsufficiency; and the identification of homozygous tenascin-X mutations in four of the five tenascin-X–deficient patients.
Although more study is needed to determine whether other conditions are associated with tenascin-X deficiency, the list of coexisting diseases in this cohort with isolated tenascin-X deficiency is striking (Table 2) and suggests that tenascin-X deficiency may be a particularly debilitating form of the Ehlers–Danlos syndrome. The diagnosis should be considered in patients with the Ehlers–Danlos syndrome who do not have atrophic scars and in those without affected family members, or when the disease is confined to one generation. The availability of a simple serum-based test for tenascin-X deficiency should make accurate diagnosis of this deficiency possible in populations with the Ehlers–Danlos syndrome and should lead to more widespread recognition of this variant.
Despite a decade of intensive investigation, very little is known about the functions of the tenascins.15,25,30 Patients with isolated tenascin-X deficiency provide evidence of an in vivo function of the tenascins, though it is not yet clear how tenascin-X deficiency leads to the Ehlers–Danlos syndrome. Several mechanisms of action of tenascin-X are possible. Tenascin-X may be an important structural component of the affected connective tissues. The fibronectin type III repeats of titin and tenascin-C may be capable of reversible unfolding and refolding and may thus act as serial elastic elements.31 Tenascin-X appears to be associated with collagen fibrils,32,33 so tenascin-X may act as an elastic element linking adjacent collagen fibrils and limiting the deformability of collagenous matrix.
Tenascin-X may also affect fibrillar collagen synthesis or fibrillogenesis. Type V collagen expression appears to be normal in tenascin-X–deficient patients, but the synthesis of other fibrillar collagens has not been examined.
Finally, it is possible that tenascin-X regulates collagen deposition. Although the structure of fibrils is normal in tenascin-X–deficient patients, the density of the collagenous matrix in the skin appears to be reduced (Figure 2). During development, tenascin-X expression is maximal when the connective-tissue scaffolding for muscle, tendon, and ligament is being laid down,18 suggesting that tenascin-X may influence the tissue-specific forms that fibrillar collagens assume.34 The search for additional causes of the Ehlers–Danlos syndrome should now extend beyond the collagens.
Supported by grants from the National Institutes of Health (HL02695, to Dr. Bristow, and DK37922 and DK42154, to Dr. Miller), the March of Dimes Birth Defects Foundation (to Dr. Bristow), and the University Medical Center Nijmegen (to Dr. Schalkwijk).
We are indebted to Dr. B. Hamel (Department of Human Genetics), Dr. B. van Engelen (Department of Neurology), Mrs. M. Kooijmans-Otero (Department of Dermatology), and Dr. M. Latijnhouwers (Department of Dermatology) — all of the University Medical Center Nijmegen, Nijmegen, the Netherlands — for their advice and technical assistance.
Source Information
From the Department of Dermatology, University Medical Center Nijmegen, Nijmegen, the Netherlands (J.S., M.C.Z., P.M.S., I.M.V., B.H.); and the Department of Pediatrics, University of California at San Francisco, San Francisco (W.B.D., G.T., W.L.M., J.B.).
Address reprint requests to Dr. Bristow at the University of California at San Francisco, Laurel Heights Campus, 3333 California St., Box 1245, San Francisco, CA 94118, or at jbristow@pedcard.ucsf.edu, or to Dr. Schalkwijk at the Department of Dermatology, UMCN, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands, or at j.schalkwijk@derma.azn.nl
- References
References
1
Beighton P ,de Paepe A ,Danks D , et al. International Nosology of Heritable Disorders of Connective Tissue, Berlin, 1986. Am J Med Genet 1988;29:581-594
CrossRef | Web of Science | Medline2
Beighton P ,De Paepe A ,Steinmann B ,Tsipouras P ,Wenstrup RJ . Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Am J Med Genet 1998;77:31-37
CrossRef | Web of Science | Medline3
Vogel A ,Holbrook KA ,Steinmann B ,Gitzelmann R ,Byers PH . Abnormal collagen fibril structure in the gravis form (type I) of Ehlers-Danlos syndrome. Lab Invest 1979;40:201-206
Web of Science | Medline4
Hyland J ,Ala-Kokko L ,Royce P ,Steinmann B ,Kivirikko KI ,Myllyla R . A homozygous stop codon in the lysyl hydroxylase gene in two siblings with Ehlers-Danlos syndrome type VI. Nat Genet 1992;2:228-231
CrossRef | Web of Science | Medline5
Smith LT ,Wertelecki W ,Milstone LM , et al. Human dermatosparaxis: a form of Ehlers-Danlos syndrome that results from failure to remove the amino-terminal propeptide of type I procollagen. Am J Hum Genet 1992;51:235-244
Web of Science | Medline6
Byers PH . Ehlers-Danlos syndrome: recent advances and current understanding of the clinical and genetic heterogeneity. J Invest Dermatol 1994;103:Suppl:47S-52S
CrossRef | Web of Science | Medline7
Toriello HV ,Glover TW ,Takahara K , et al. A translocation interrupts the COL5A1 gene in a patient with Ehlers-Danlos syndrome and hypomelanosis of Ito. Nat Genet 1996;13:361-365
CrossRef | Web of Science | Medline8
Giunta C ,Steinmann B . Compound heterozygosity for a disease-causing G1489D and disease-modifying G530S substitution in COL5A1 of a patient with the classical type of Ehlers-Danlos syndrome: an explanation of intrafamilial variability? Am J Med Genet 2000;90:72-79
CrossRef | Web of Science | Medline9
De Paepe A ,Nuytinck L ,Hausser I ,Anton-Lamprecht I ,Naeyaert JM . Mutations in the COL5A1 gene are causal in the Ehlers-Danlos syndromes I and II. Am J Hum Genet 1997;60:547-554
Web of Science | Medline10
Smith LT ,Schwarze U ,Goldstein J ,Byers PH . Mutations in the COL3A1 gene result in the Ehlers-Danlos syndrome type IV and alterations in the size and distribution of the major collagen fibrils of the dermis. J Invest Dermatol 1997;108:241-247
CrossRef | Web of Science | Medline11
Burrows NP ,Nicholls AC ,Richards AJ , et al. A point mutation in an intronic branch site results in aberrant splicing of COL5A1 and in Ehlers-Danlos syndrome type II in two British families. Am J Hum Genet 1998;63:390-398
CrossRef | Web of Science | Medline12
Wenstrup RJ ,Langland GT ,Willing MC ,D'Souza VN ,Cole WG . A splice-junction mutation in the region of COL5A1 that codes for the carboxyl propeptide of pro alpha 1(V) chains results in the gravis form of the Ehlers-Danlos syndrome (type I). Hum Mol Genet 1996;5:1733-1736
CrossRef | Web of Science | Medline13
Schwarze U ,Atkinson M ,Hoffman GG ,Greenspan DS ,Byers PH . Null alleles of the COL5A1 gene of type V collagen are a cause of the classical forms of Ehlers-Danlos syndrome (types I and II). Am J Hum Genet 2000;66:1757-1765
CrossRef | Web of Science | Medline14
Wenstrup RJ ,Florer JB ,Willing MC , et al. COL5A1 halpoinsufficiency is a common molecular mechanism underlying the classical form of EDS. Am J Hum Genet 2000;66:1766-1776
CrossRef | Web of Science | Medline15
Erickson HP . Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol 1993;5:869-876
CrossRef | Medline16
Schalkwijk J ,Steijlen PM ,Vlijmen-Willems IM ,Oosterling B ,Mackie EJ ,Verstraeten AA . Tenascin expression in human dermis is related to epidermal proliferation. Am J Pathol 1991;139:1143-1150
Web of Science | Medline17
Matsumoto K ,Saga Y ,Ikemura T ,Sakakura T ,Chiquet-Ehrismann R . The distribution of tenascin-X is distinct and often reciprocal to that of tenascin-C. J Cell Biol 1994;125:483-493
CrossRef | Web of Science | Medline18
Burch GH ,Bedolli MA ,McDonough S ,Rosenthal SM ,Bristow J . Embryonic expression of tenascin-X suggests a role in limb, muscle, and heart development. Dev Dyn 1995;203:491-504
CrossRef | Web of Science | Medline19
Geffrotin C ,Garrido JJ ,Tremet L ,Vaiman M . Distinct tissue distribution in pigs of tenascin-X and tenascin-C transcripts. Eur J Biochem 1995;231:83-92
CrossRef | Medline20
Mackie EJ ,Ramsey S . Expression of tenascin in joint-associated tissues during development and postnatal growth. J Anat 1996;188:157-165
Web of Science | Medline21
Morel Y ,Bristow J ,Gitelman SE ,Miller WL . Transcript encoded on the opposite strand of the human steroid 21-hydroxylase/complement component C4 gene locus. Proc Natl Acad Sci U S A 1989;86:6582-6586
CrossRef | Web of Science | Medline22
Bristow J ,Tee MK ,Gitelman SE ,Mellon SH ,Miller WL . Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J Cell Biol 1993;122:265-278
CrossRef | Web of Science | Medline23
Burch GH ,Gong Y ,Liu W , et al. Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nat Genet 1997;17:104-108
CrossRef | Web of Science | Medline24
Erickson HP . Gene knockouts of c-src, transforming growth factor beta 1, and tenascin suggest superfluous, nonfunctional expression of proteins. J Cell Biol 1993;120:1079-1081
CrossRef | Web of Science | Medline25
Erickson HP . A tenascin knockout with a phenotype. Nat Genet 1997;17:5-7
CrossRef | Web of Science | Medline26
Tee MK ,Thomson AA ,Bristow J ,Miller WL . Sequences promoting the transcription of the human XA gene overlapping P450c21A correctly predict the presence of a novel, adrenal-specific, truncated form of tenascin-X. Genomics 1995;28:171-178
CrossRef | Web of Science | Medline27
Verstraeten AA ,Mackie EJ ,Hageman PC , et al. Tenascin expression in basal cell carcinoma. Br J Dermatol 1992;127:571-574
CrossRef | Web of Science | Medline28
Latijnhouwers MA ,Bergers M ,Kuijpers AL , et al. Tenascin-C is not a useful marker for disease activity in psoriasis. Acta Derm Venereol 1998;78:331-334
CrossRef | Web of Science | Medline29
Gitelman SE ,Bristow J ,Miller WL . Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus. Mol Cell Biol 1992;12:2124-2134[Erratum, Mol Cell Biol 1992;12:3313-4.]
Web of Science | Medline30
Mackie EJ ,Tucker RP . The tenascin-C knockout revisited. J Cell Sci 1999;112:3847-3853
Web of Science | Medline31
Oberhauser AF ,Marszalek PE ,Erickson HP ,Fernandez JM . The molecular elasticity of the extracellular matrix protein tenascin. Nature 1998;393:181-185
CrossRef | Web of Science | Medline32
Elefteriou F ,Exposito JY ,Garrone R ,Lethias C . Characterization of the bovine tenascin-X. J Biol Chem 1997;272:22866-22874
CrossRef | Web of Science | Medline33
Lethias C ,Descollonges Y ,Boutillon MM ,Garrone R . Flexilin: a new extracellular matrix glycoprotein localized on collagen fibrils. Matrix Biol 1996;15:11-19
CrossRef | Web of Science | Medline34
Mao JR ,Bristow J . The Ehlers-Danlos syndrome: on beyond collagens. J Clin Invest 2001;107:1063-1069
CrossRef | Web of Science | Medline
- Citing Articles (95)
Citing Articles
1
Maria Luisa Bianchi, Francis H. Glorieux. 2012. The Spectrum of Pediatric Osteoporosis. , 439-509.
CrossRef2
Tomoki Kosho, Noriko Miyake, Shuji Mizumoto, Atsushi Hatamochi, Yoshimitsu Fukushima, Shuhei Yamada, Kazuyuki Sugahara, Naomichi Matsumoto. (2011) A response to: Loss of dermatan-4-sulfotransferase 1 (D4ST1/CHST14) function represents the first dermatan sulfate biosynthesis defect, “dermatan sulfate-deficient Adducted Thumb-Clubfoot Syndrome”. Which name is appropriate, “Adducted Thumb-Clubfoot Synd. Human Mutation 32:12, 1507-1509
CrossRef3
Jeannine Coreil, Jaime A. Corvin, Rebecca Nupp, Karen Dyer, Charlotte Noble. (2011) Ethnicity and cultural models of recovery from breast cancer. Ethnicity & Health1-17
CrossRef4
N. C. Voermans, K. Verrijp, L. Eshuis, M. C. M. Balemans, D. Egging, E. Sterrenburg, I. A. L. M. van Rooij, J. A. W. M. van der Laak, J. Schalkwijk, S. M van der Maarel, M. Lammens, B. G. van Engelen. (2011) Mild Muscular Features in Tenascin-X Knockout Mice, A Model of Ehlers–Danlos Syndrome. Connective Tissue Research 52:5, 422-432
CrossRef5
Angel O.K. Chan, W.M. But, K.L. Ng, L.M. Wong, Y.Y. Lam, S.C. Tiu, K.F. Lee, C.Y. Lee, P.Y. Loung, Ian R. Berry, Rebecca Brown, Ruth Charlton, C.W. Cheng, Y.C. Ho, W.Y. Tse, C.C. Shek. (2011) Molecular analysis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Hong Kong Chinese patients. Steroids 76:10-11, 1057-1062
CrossRef6
Thomas Krieg, Monique Aumailley. (2011) The extracellular matrix of the dermis: flexible structures with dynamic functions. Experimental Dermatology 20:8, 689-695
CrossRef7
Zhi Zeng, Marina Hincapie, Sharon J. Pitteri, Samir Hanash, Joost Schalkwijk, Jason M. Hogan, Hong Wang, William S. Hancock. (2011) A Proteomics Platform Combining Depletion, Multi-lectin Affinity Chromatography (M-LAC), and Isoelectric Focusing to Study the Breast Cancer Proteome. Analytical Chemistry 83:12, 4845-4854
CrossRef8
Nigel P. Burrows, Navjeet Sidhu-Malik, Heather N. Yeowell. 2011. Ehlers-Danlos Syndromes. , 142.1-142.15.
CrossRef9
Selma Feldman Witchel, Ricardo Azziz. (2011) Congenital Adrenal Hyperplasia. Journal of Pediatric and Adolescent Gynecology 24:3, 116-126
CrossRef10
N.C. Voermans, H. Knoop, G. Bleijenberg, B.G. van Engelen. (2011) Fatigue is associated with muscle weakness in Ehlers-Danlos syndrome: an explorative study. Physiotherapy 97:2, 170-174
CrossRef11
Kohei Kawakami, Ken-ichi Matsumoto. (2011) Behavioral Alterations in Mice Lacking the Gene for Tenascin-X. Biological & Pharmaceutical Bulletin 34:4, 590-593
CrossRef12
M. O’Connell, N.P. Burrows, M.J.J. Van Vlijmen-Willems, S.M. Clark, J. Schalkwijk. (2010) Tenascin-X deficiency and Ehlers-Danlos syndrome: a case report and review of the literature. British Journal of Dermatology 163:6, 1340-1345
CrossRef13
Nicol C. Voermans, Hans Knoop, Nicole van de Kamp, Ben C. Hamel, Gijs Bleijenberg, Baziel G. van Engelen. (2010) Fatigue Is a Frequent and Clinically Relevant Problem in Ehlers-Danlos Syndrome. Seminars in Arthritis and Rheumatism 40:3, 267-274
CrossRef14
Fransiska Malfait, Delfien Syx, Philip Vlummens, Sofie Symoens, Sheela Nampoothiri, Trinh Hermanns-Lê, Lut Van Laer, Anne De Paepe. (2010) Musculocontractural Ehlers-Danlos Syndrome (former EDS type VIB) and adducted thumb clubfoot syndrome (ATCS) represent a single clinical entity caused by mutations in the dermatan-4-sulfotransferase 1 encoding CHST14 gene. Human Mutation 31:11, 1233-1239
CrossRef15
Fransiska Malfait, Richard J. Wenstrup, Anne De Paepe. (2010) Clinical and genetic aspects of Ehlers-Danlos syndrome, classic type. Genetics in Medicine 12:10, 597-605
CrossRef16
Marco Castori, Filippo Camerota, Claudia Celletti, Paola Grammatico, Luca Padua. (2010) Ehlers-Danlos syndrome hypermobility type and the excess of affected females: Possible mechanisms and perspectives. American Journal of Medical Genetics Part A 152A:9, 2406-2408
CrossRef17
Nicol C. Voermans, Hans Knoop, Gijs Bleijenberg, Baziel G. van Engelen. (2010) Pain in Ehlers-Danlos Syndrome Is Common, Severe, and Associated with Functional Impairment. Journal of Pain and Symptom Management 40:3, 370-378
CrossRef18
Paola Concolino, Enrica Mello, Cecilia Zuppi, Ettore Capoluongo. (2010) Molecular diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: an update of new CYP21A2 mutations. Clinical Chemistry and Laboratory Medicine 48:8, 1057-1062
CrossRef19
A. P. Barannik, A. A. Koltunova, L. A. Ozolinya, N. V. Lavrova, I. A. Shilov, I. I. Guzov, L. I. Patrushev. (2010) A new DNA diagnostic system for the detection of human CYP21 gene mutations associated with adrenal cortex hyperplasia. Russian Journal of Bioorganic Chemistry 36:3, 325-335
CrossRef20
Maureen Murphy-Ryan, Apostolos Psychogios, Noralane M. Lindor. (2010) Hereditary disorders of connective tissue: a guide to the emerging differential diagnosis. Genetics in Medicine1
CrossRef21
N. P. Burrows, C. R. Lovell. 2010. Disorders of Connective Tissue. , 1-70.
CrossRef22
Marco Castori, Filippo Camerota, Claudia Celletti, Chiara Danese, Valter Santilli, Vincenzo Maria Saraceni, Paola Grammatico. (2010) Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: A pilot study on 21 patients. American Journal of Medical Genetics Part A 152A:3, 556-564
CrossRef23
Yoran Margaron, Luciana Bostan, Jean-Yves Exposito, Maryline Malbouyres, Ana-Maria Trunfio-Sfarghiu, Yves Berthier, Claire Lethias. (2010) Tenascin-X increases the stiffness of collagen gels without affecting fibrillogenesis. Biophysical Chemistry 147:1-2, 87-91
CrossRef24
Selma Feldman Witchel, Ricardo Azziz. (2010) Nonclassic Congenital Adrenal Hyperplasia. International Journal of Pediatric Endocrinology 2010, 1-11
CrossRef25
Kazumi Satoh, Marie Tsukamoto, Masanobu Shindoh, Yasunori Totsuka, Teiji Oda, Ken-ichi Matsumoto. (2010) Increased Expression of Tenascin-X in Thoracic and Abdominal Aortic Aneurysm Tissues. Biological & Pharmaceutical Bulletin 33:11, 1898-1902
CrossRef26
SelmaFeldman Witchel, Ricardo Azziz. (2010) NonClassic Congenital Adrenal Hyperplasia. International Journal of Pediatric Endocrinology 2010:1, 625105
CrossRef27
Tomoki Kosho, Noriko Miyake, Atsushi Hatamochi, Jun Takahashi, Hiroyuki Kato, Teruyoshi Miyahara, Yasuhiko Igawa, Hiroshi Yasui, Tadao Ishida, Kurahito Ono, Takashi Kosuda, Akihiko Inoue, Mohei Kohyama, Tadashi Hattori, Hirofumi Ohashi, Gen Nishimura, Rie Kawamura, Keiko Wakui, Yoshimitsu Fukushima, Naomichi Matsumoto. (2010) A new Ehlers-Danlos syndrome with craniofacial characteristics, multiple congenital contractures, progressive joint and skin laxity, and multisystem fragility-related manifestations. American Journal of Medical Genetics Part An/a-n/a
CrossRef28
J SHAPIRO. 2010. Inherited and Related Disorders of Bone Matrix Synthesis in Men. , 505-522.
CrossRef29
Wuyan Chen, Mimi S. Kim, Sujata Shanbhag, Andrew Arai, Carol VanRyzin, Nazli B. McDonnell, Deborah P. Merke. (2009) The phenotypic spectrum of contiguous deletion of CYP21A2 and tenascin XB: Quadricuspid aortic valve and other midline defects. American Journal of Medical Genetics Part A 149A:12, 2803-2808
CrossRef30
Li-Ping Tsai, Ching-Feng Cheng, Jo-Ping Hsieh, Ming-sheng Teng, Hsien-Hsiung Lee. (2009) Application of the DHPLC method for mutational detection of the CYP21A2 gene in congenital adrenal hyperplasia. Clinica Chimica Acta 410:1-2, 48-53
CrossRef31
Fransiska Malfait, Anne De Paepe. (2009) Bleeding in the heritable connective tissue disorders: Mechanisms, diagnosis and treatment. Blood Reviews 23:5, 191-197
CrossRef32
Richard Collinge, Jane V. Simmonds. (2009) Hypermobility, injury rate and rehabilitation in a professional football squad – A preliminary study. Physical Therapy in Sport 10:3, 91-96
CrossRef33
Walter L. Miller. 2009. The Adrenal Cortex and its Disorders. , 283-326.
CrossRef34
Nicol C. Voermans, Nens van Alfen, Sigrid Pillen, Martin Lammens, Joost Schalkwijk, Machiel J. Zwarts, Iris A. van Rooij, Ben C. J. Hamel, Baziel G. van Engelen. (2009) Neuromuscular involvement in various types of Ehlers-Danlos syndrome. Annals of Neurology 65:6, 687-697
CrossRef35
Yann-Jinn Lee, Li-Ping Tsai, Dau-Ming Niu, San-Ging Shu, Mei-Chyn Chao, Hsien-Hsiung Lee. (2009) The gene founder effect of two spontaneous mutations in ethnic Chinese (Taiwanese) CAH patients with 21-hydroxylase deficiency. Molecular Genetics and Metabolism 97:1, 75-79
CrossRef36
Douglas J. Rhee, Ramez I. Haddadin, Min Hyung Kang, Dong-Jin Oh. (2009) Matricellular proteins in the trabecular meshwork. Experimental Eye Research 88:4, 694-703
CrossRef37
Nand L. Sharma, Vikram K. Mahajan, Neelam Gupta, Nitin Ranjan, Anju Lath. (2009) Ehlers-Danlos syndrome - vascular type (ecchymotic variant): cutaneous and dermatopathologic features. Journal of Cutaneous Pathology 36:4, 486-492
CrossRef38
N. C. Voermans, C. G. Bonnemann, B. C. J. Hamel, H. Jungbluth, B. G. Engelen. (2009) Joint hypermobility as a distinctive feature in the differential diagnosis of myopathies. Journal of Neurology 256:1, 13-27
CrossRef39
Shinpei Fujie, Hiroshi Maita, Hiroyoshi Ariga, Ken-ichi Matsumoto. (2009) Tenascin-X Induces Cell Detachment through p38 Mitogen-Activated Protein Kinase Activation. Biological & Pharmaceutical Bulletin 32:10, 1795-1799
CrossRef40
Taichi Ishitsuka, Tomoki Ikuta, Hiroyoshi Ariga, Ken-ichi Matsumoto. (2009) Serum Tenascin-X Strongly Binds to Vascular Endothelial Growth Factor. Biological & Pharmaceutical Bulletin 32:6, 1004-1011
CrossRef41
N.C. Voermans, C.G. Bönnemann, P.A. Huijing, B.C. Hamel, T.H. van Kuppevelt, A. de Haan, J. Schalkwijk, B.G. van Engelen, G.J. Jenniskens. (2008) Clinical and molecular overlap between myopathies and inherited connective tissue diseases. Neuromuscular Disorders 18:11, 843-856
CrossRef42
Yung-Te Tseng, Hsien-Hsiung Lee, Yann-Jinn Lee. (2008) An investigation of the C4 gene arrangement in ethnic Chinese (Taiwanese). International Journal of Immunogenetics 35:4-5, 323-329
CrossRef43
David F. Egging, Ivonne Vlijmen-Willems, Jiwon Choi, Anita C. T. M. Peeters, Desiree Rens, Guido Veit, Manuel Koch, Elaine C. Davis, Joost Schalkwijk. (2008) Analysis of obstetric complications and uterine connective tissue in tenascin-X-deficient humans and mice. Cell and Tissue Research 332:3, 523-532
CrossRef44
Bert Callewaert, Fransiska Malfait, Bart Loeys, Anne De Paepe. (2008) Ehlers-Danlos syndromes and Marfan syndrome. Best Practice & Research Clinical Rheumatology 22:1, 165-189
CrossRef45
WALTER L. MILLER, JOHN C. ACHERMANN, CHRISTA E. FLÜCK. 2008. The Adrenal Cortex and Its Disorders. , 444-511.
CrossRef46
Rodney Grahame, Alan J Hakim. (2008) Hypermobility. Current Opinion in Rheumatology 20:1, 106-110
CrossRef47
N.C. Voermans, G.J. Jenniskens, B.C. Hamel, J. Schalkwijk, P. Guicheney, B.G. van Engelen. (2007) Ehlers–Danlos syndrome due to tenascin-X deficiency: Muscle weakness and contractures support overlap with collagen VI myopathies. American Journal of Medical Genetics Part A 143A:18, 2215-2219
CrossRef48
Trinh Hermanns-L??, G??rald E Pi??rard. (2007) Ultrastructural Alterations of Elastic Fibers and Other Dermal Components in Ehlers-Danlos Syndrome of the Hypermobile Type. The American Journal of Dermatopathology 29:4, 370-373
CrossRef49
N.C. Voermans, T.M. Altenburg, B.C. Hamel, A. de Haan, B.G. van Engelen. (2007) Reduced quantitative muscle function in tenascin-X deficient Ehlers-Danlos patients. Neuromuscular Disorders 17:8, 597-602
CrossRef50
Robert Nakayama, Takeshi Nemoto, Hiro Takahashi, Tsutomu Ohta, Akira Kawai, Kunihiko Seki, Teruhiko Yoshida, Yoshiaki Toyama, Hitoshi Ichikawa, Tadashi Hasegawa. (2007) Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Modern Pathology 20:7, 749-759
CrossRef51
Yan Yang, Erwin K. Chung, Yee Ling Wu, Stephanie L. Savelli, Haikady N. Nagaraja, Bi Zhou, Maddie Hebert, Karla N. Jones, Yaoling Shu, Kathryn Kitzmiller, Carol A. Blanchong, Kim L. McBride, Gloria C. Higgins, Robert M. Rennebohm, Robert R. Rice, Kevin V. Hackshaw, Robert A.S. Roubey, Jennifer M. Grossman, Betty P. Tsao, Daniel J. Birmingham, Brad H. Rovin, Lee A. Hebert, C. Yung Yu. (2007) Gene Copy-Number Variation and Associated Polymorphisms of Complement Component C4 in Human Systemic Lupus Erythematosus (SLE): Low Copy Number Is a Risk Factor for and High Copy Number Is a Protective Factor against SLE Susceptibility in European Americans. The American Journal of Human Genetics 80:6, 1037-1054
CrossRef52
Mamoru Tochigi, Xuan Zhang, Jun Ohashi, Hiroyuki Hibino, Takeshi Otowa, Mark Rogers, Tadafumi Kato, Yuji Okazaki, Nobumasa Kato, Katsushi Tokunaga, Tsukasa Sasaki. (2007) Association study between the TNXB locus and schizophrenia in a Japanese population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 144B:3, 305-309
CrossRef53
D. F. Egging, A. C. T. M. Peeters, N. Grebenchtchikov, A. Geurts-Moespot, C. G. J. Sweep, M. den Heijer, J. Schalkwijk. (2007) Identification and characterization of multiple species of tenascin-X in human serum. FEBS Journal 274:5, 1280-1289
CrossRef54
Takeshi Kinoshita, Hiroyoshi Ariga, Ken-ichi Matsumoto. (2007) Distinct Glycosylation in Interstitial and Serum Tenascin-X. Biological & Pharmaceutical Bulletin 30:2, 354-358
CrossRef55
David Egging, Franka Berkmortel, Glen Taylor, Jim Bristow, Joost Schalkwijk. (2006) Interactions of human tenascin-X domains with dermal extracellular matrix molecules. Archives of Dermatological Research 298:8, 389-396
CrossRef56
Hsien-Hsiung Lee, Fuu-Jen Tsai, Yann-Jinn Lee, Yuh-Cheng Yang. (2006) Diversity of the CYP21A2 gene: A 6.2-kb TaqI fragment and a 3.2-kb TaqI fragment mistaken as CYP21A1P. Molecular Genetics and Metabolism 88:4, 372-377
CrossRef57
Ken-Ichi Matsumoto, Takeshi Kinoshita, Tomohiro Hirose, Hiroyoshi Ariga. (2006) Characterization of Mouse Serum Tenascin-X. DNA and Cell Biology 25:8, 448-456
CrossRef58
N. C. Voermans, G. Drost, A. Kampen, A. A. Gabreëls–Festen, M. Lammens, B. C. Hamel, J. Schalkwijk, B. G. Engelen. (2006) Recurrent neuropathy associated with Ehlers–Danlos syndrome. Journal of Neurology 253:5, 670-671
CrossRef59
D. F. Egging, I. Vlijmen, B. Starcher, Y. Gijsen, M. C. Zweers, L. Blankevoort, J. Bristow, J. Schalkwijk. (2006) Dermal connective tissue development in mice: an essential role for tenascin-X. Cell and Tissue Research 323:3, 465-474
CrossRef60
Fransiska Malfait, Anne de Paepe. (2005) Molecular genetics inclassic Ehlers-Danlos syndrome. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 139C:1, 17-23
CrossRef61
James Bristow, William Carey, David Egging, Joost Schalkwijk. (2005) Tenascin-X, collagen, elastin, and the Ehlers-Danlos syndrome. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 139C:1, 24-30
CrossRef62
Noralane M. Lindor, James Bristow. (2005) Tenascin-X deficiency in autosomal recessive Ehlers-Danlos syndrome. American Journal of Medical Genetics Part A 135A:1, 75-80
CrossRef63
MC Zweers, WB Dean, TH Van Kuppevelt, J Bristow, J Schalkwijk. (2005) Elastic fiber abnormalities in hypermobility type Ehlers-Danlos syndrome patients with tenascin-X mutations. Clinical Genetics 67:4, 330-334
CrossRef64
SHE Zaidi, V Peltekova, S Meyer, A Lindinger, AD Paterson, L-C Tsui, M Faiyaz-Ul-Haque, AS Teebi. (2005) A family exhibiting arterial tortuosity syndrome displays homozygosity for markers in the arterial tortuosity locus at chromosome 20q13. Clinical Genetics 67:2, 183-188
CrossRef65
Manon C. Zweers, Joost Schalkwijk, Toin H. Kuppevelt, Ivonne M. Vlijmen-Willems, Mieke Bergers, Claire Lethias, Evert N. Lamme. (2005) Transplantation of reconstructed human skin on nude mice: a model system to study expression of human tenascin-X and elastic fiber components. Cell and Tissue Research 319:2, 279-287
CrossRef66
Richard J. Wenstrup, Leah B. Hoechstetter. 2005. Ehlers-Danlos Syndromes. .
CrossRef67
Hsien-Hsiung Lee. (2005) Diversity of the CYP21P -Like Gene in CYP21 Deficiency. DNA and Cell Biology 24:1, 1-9
CrossRef68
Fransiska Malfait, Paul Coucke, Sofie Symoens, Bart Loeys, Lieve Nuytinck, Anne De Paepe. (2005) The molecular basis of classic Ehlers-Danlos syndrome: A comprehensive study of biochemical and molecular findings in 48 unrelated patients. Human Mutation 25:1, 28-37
CrossRef69
Phyllis W. Speiser. (2005) The Genetics of Steroid 21-Hydroxylase Deficiency. The Endocrinologist 15:1, 37-43
CrossRef70
Anne De Paepe, Paul Coucke, Fransiska Malfait. 2004. Ehlers–Danlos Syndrome. , 380-385.
CrossRef71
L.C. Walker, M.A. Overstreet, M.C. Willing, J.C. Marini, W.A. Cabral, G. Pals, J. Bristow, P. Atsawasuwan, M. Yamauchi, Heather N. Yeowell. (2004) Heterogeneous basis of the type VIB form of Ehlers-Danlos syndrome (EDS VIB) that is unrelated to decreased collagen lysyl hydroxylation. American Journal of Medical Genetics 131A:2, 155-162
CrossRef72
Anne De Paepe, Fransiska Malfait. (2004) Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. British Journal of Haematology 127:5, 491-500
CrossRef73
Manon C. Zweers, Alan J. Hakim, Rodney Grahame, Joost Schalkwijk. (2004) Joint hypermobility syndromes: The pathophysiologic role of tenascin-X gene defects. Arthritis & Rheumatism 50:9, 2742-2749
CrossRef74
Ken-ichi Matsumoto, Takashige Sato, Seiko Oka, Yasuko Orba, Hirofumi Sawa, Kazuya Kabayama, Jin-ichi Inokuchi, Hiroyoshi Ariga. (2004) Triglyceride accumulation and altered composition of triglyceride-associated fatty acids in the skin of tenascin-X-deficient mice. Genes to Cells 9:8, 737-748
CrossRef75
STEPHEN D. WHITE, VERENA K. AFFOLTER, DANIKA L. BANNASCH, PATRICIA C. SCHULTHEISS, DWAYNE W. HAMAR, PHILLIP L. CHAPMAN, DIANE NAYDAN, SHARON J. SPIER, ROD A. W. ROSYCHUK, CHRISTINE REES, GREGG O. VENEKLASEN, ALONDRA MARTIN, DIANE BEVIER, HILARY A. JACKSON, SONYA BETTENAY, JENNIFER MATOUSEK, KAREN L. CAMPBELL, PETER J. IHRKE. (2004) Hereditary equine regional dermal asthenia ('hyperelastosis cutis') in 50 horses: clinical, histological, immunohistological and ultrastructural findings. Veterinary Dermatology 15:4, 207-217
CrossRef76
Takeharu Minamitani, Tomoki Ikuta, Yoshinari Saito, Gen Takebe, Mami Sato, Hirofumi Sawa, Takanori Nishimura, Fumio Nakamura, Kazuhiko Takahashi, Hiroyoshi Ariga, Ken-ichi Matsumoto. (2004) Modulation of collagen fibrillogenesis by tenascin-X and type VI collagen. Experimental Cell Research 298:1, 305-315
CrossRef77
Takeharu Minamitani, Hiroyoshi Ariga, Ken-ichi Matsumoto. (2004) Deficiency of tenascin-X causes a decrease in the level of expression of type VI collagen. Experimental Cell Research 297:1, 49-60
CrossRef78
Ken-ichi Matsumoto, Takeharu Minamitani, Yasuko Orba, Mami Sato, Hirofumi Sawa, Hiroyoshi Ariga. (2004) Induction of matrix metalloproteinase-2 by tenascin-X deficiency is mediated through the c-Jun N-terminal kinase and protein tyrosine kinase phosphorylation pathway. Experimental Cell Research 297:2, 404-414
CrossRef79
Ruth Chiquet-Ehrismann, Richard P. Tucker. (2004) Connective tissues: signalling by tenascins. The International Journal of Biochemistry & Cell Biology 36:6, 1085-1089
CrossRef80
Ulrike Schwarze, Ryu-Ichiro Hata, Victor A. McKusick, Hiroshi Shinkai, H. Eugene Hoyme, Reed E. Pyeritz, Peter H. Byers. (2004) Rare Autosomal Recessive Cardiac Valvular Form of Ehlers-Danlos Syndrome Results from Mutations in the COL1A2 Gene That Activate the Nonsense-Mediated RNA Decay Pathway. The American Journal of Human Genetics 74:5, 917-930
CrossRef81
Richard J. Wenstrup, Jane B. Florer, William G. Cole, Marcia C. Willing, David E. Birk. (2004) Reduced type I collagen utilization: A pathogenic mechanism in COL5A1 haplo-insufficient Ehlers-Danlos syndrome. Journal of Cellular Biochemistry 92:1, 113-124
CrossRef82
Jouni Uitto, Franziska Ringpfeil. (2004) Ehlers-Danlos Syndrome-Molecular Genetics Beyond the Collagens. Journal of Investigative Dermatology 122:4, xii-xii
CrossRef83
Manon C. Zweers, Ivonne M. van Vlijmen-Willems, Toin H. van Kuppevelt, Robert P. Mecham, Peter M. Steijlen, Jim Bristow, Joost Schalkwijk. (2004) Deficiency of Tenascin-X Causes Abnormalities in Dermal Elastic Fiber Morphology. Journal of Investigative Dermatology 122:4, 885-891
CrossRef84
J. Wei, G.P. Hemmings. (2004) TNXB locus may be a candidate gene predisposing to schizophrenia. American Journal of Medical Genetics 125B:1, 43-49
CrossRef85
N RAHMAN, M DUNSTAN, M TEARE, S HANKS, J DOUGLAS, K COLEMAN, W BOTTOMLY, M CAMPBELL, B BERGLUND, M NORDENSKJOLD. (2003) Ehlers-Danlos Syndrome with Severe Early-Onset Periodontal Disease (EDS-VIII) Is a Distinct, Heterogeneous Disorder with One Predisposition Gene at Chromosome 12p13. The American Journal of Human Genetics 73:1, 198-204
CrossRef86
M ZWEERS, J BRISTOW, P STEIJLEN, W DEAN, B HAMEL, M OTERO, M KUCHAREKOVA, J BOEZEMAN, J SCHALKWIJK. (2003) Haploinsufficiency of TNXB Is Associated with Hypermobility Type of Ehlers-Danlos Syndrome. The American Journal of Human Genetics 73:1, 214-217
CrossRef87
Ruth Chiquet-Ehrismann, Matthias Chiquet. (2003) Tenascins: regulation and putative functions during pathological stress. The Journal of Pathology 200:4, 488-499
CrossRef88
Jouni Uitto, Leena Pulkkinen, Franziska Ringpfeil. (2002) Progress in Molecular Genetics of Heritable Skin Diseases: The Paradigms of Epidermolysis Bullosa and Pseudoxanthoma Elasticum. Journal of Investigative Dermatology Symposium Proceedings 7:1, 6-16
CrossRef89
Eugene Y. Kissin, Raphael Lemaire, Joseph H. Korn, Robert Lafyatis. (2002) Transforming growth factor ? induces fibroblast fibrillin-1 matrix formation. Arthritis & Rheumatism 46:11, 3000-3009
CrossRef90
Sujeewa D Wijesuriya, James Bristow, Walter L Miller. (2002) Localization and Analysis of the Principal Promoter for Human Tenascin-X. Genomics 80:4, 443-452
CrossRef91
Kazuhiko Takahara, Ulrike Schwarze, Yasutada Imamura, Guy G. Hoffman, Helga Toriello, Lynne T. Smith, Peter H. Byers, Daniel S. Greenspan. (2002) Order of Intron Removal Influences Multiple Splice Outcomes, Including a Two-Exon Skip, in a COL5A1 Acceptor-Site Mutation That Results in Abnormal Pro-α1(V) N-Propeptides and Ehlers-Danlos Syndrome Type I. The American Journal of Human Genetics 71:3, 451-465
CrossRef92
Taina Jaatinen, Erwin K Chung, Olli Ruuskanen, Marja-Liisa Lokki. (2002) An unequal crossover event in RCCX modules of the human MHC resulting in the formation of a TNXB/TNXA hybrid and deletion of the CYP21A. Human Immunology 63:8, 683-689
CrossRef93
C. Giunta, L. Nuytinck, M. Raghunath, I. Hausser, A. De Paepe, B. Steinmann. (2002) Homozygous Gly530Ser substitution inCOL5A1 causes mild classical Ehlers-Danlos syndrome. American Journal of Medical Genetics 109:4, 284-290
CrossRef94
Takeharu Minamitani, Hiroyoshi Ariga, Ken-ichi Matsumoto. (2002) Adhesive Defect in Extracellular Matrix Tenascin-X-Null Fibroblasts: A Possible Mechanism of Tumor Invasion. Biological & Pharmaceutical Bulletin 25:11, 1472-1475
CrossRef95
Byers, Peter H., . (2001) An Exception to the Rule. New England Journal of Medicine 345:16, 1203-1205
Full Text
